Shots:

• Bluebird plans to separate its severe genetic disease & oncology businesses into differentiated and independent publicly traded companies. The company will retain focus on SGD and will launch its oncology business (“Oncology Newco”) as a new entity
• The spinoff is expected to result in two independent- publicly traded companies by the end of 2021
• The spinoff is designed to unlock value through improved operational execution- organizational focus- tailored capital allocation- and enhanced strategic optionality

 ­ Ref: Businesswire | Image: Fierce Pharma